# PTC Inc.: Form 10-Q for the period ended Mar 31, 2023

- Company: [PTC Inc.](/companies/ptc.md) (CIK 857005)
- Form: 10-Q
- Filed: 2023-05-03
- Accepted by EDGAR: May 3, 2023, 16:10 ET
- Period: 2023-03-31
- Accession: 0000950170-23-017177
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/857005/000095017023017177/ptc-20230331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/857005/000095017023017177/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-01-01 to 2023-03-31 | $542.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-10-01 to 2023-03-31 | $1.01bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2023-01-01 to 2023-03-31 | $113.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2022-10-01 to 2023-03-31 | $209.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2023-01-01 to 2023-03-31 | $428.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2022-10-01 to 2023-03-31 | $798.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2023-01-01 to 2023-03-31 | $100.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-10-01 to 2023-03-31 | $188.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2023-01-01 to 2023-03-31 | $122.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-10-01 to 2023-03-31 | $227.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-01-01 to 2023-03-31 | $41.5m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2022-10-01 to 2023-03-31 | $57.9m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-01-01 to 2023-03-31 | $17.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-10-01 to 2023-03-31 | $29.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-01-01 to 2023-03-31 | $63.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-10-01 to 2023-03-31 | $138.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.53 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-10-01 to 2023-03-31 | $1.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-01-01 to 2023-03-31 | $0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-10-01 to 2023-03-31 | $1.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-01-01 to 2023-03-31 | 119,041,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-10-01 to 2023-03-31 | 118,912,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-10-01 to 2023-03-31 | $391.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-10-01 to 2023-03-31 | $12.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2022-10-01 to 2023-03-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-03-31 | $320.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-03-31 | $1.17bn | us-gaap:AssetsCurrent |
| Total assets | at 2023-03-31 | $6.30bn | us-gaap:Assets |
| Current liabilities | at 2023-03-31 | $1.59bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-03-31 | $3.78bn | us-gaap:Liabilities |
| Long-term debt | at 2023-03-31 | $1.92bn | us-gaap:LongTermDebt |
| Shareholders' equity | at 2023-03-31 | $2.52bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/857005/000095017023017177/ptc-20230331.htm

Filed May 3, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-017177. Last ingested by Listed: Nov 14, 2026, 20:17 ET. No prices; not investment advice.
